Supplementary Quarterly Financial Data (Unaudited) (Tables)

6 Months Ended

Dec. 31, 2020

Quarterly Financial Information Disclosure [Abstract]


(in millions)	Quarters Ended
Consolidated Statement of Operations Data:	December 31, 2020		September 30, 2020
Molecular diagnostic testing	$	143.9	$	135.7
Pharmaceutical and clinical services	10.7		9.5
Total revenue	154.6		145.2
Costs and expenses:
Cost of molecular diagnostic testing	42.7		39.9
Cost of pharmaceutical and clinical services	4.5		4.3
Research and development expense	18.2		17.6
Change in the fair value of contingent consideration	4.6		(1.1)
Selling, general and administrative expense	132.8		124.1
Total costs and expenses	202.8		184.8
Operating loss	(48.2)		(39.6)
Other income (expense):
Interest income	0.3		0.4
Interest expense	(2.9)		(2.9)
Other	0.4		(1.6)
Total other expense	(2.2)		(4.1)
Loss before income taxes	(50.4)		(43.7)
Income tax benefit	(12.5)		(28.5)
Net loss	(37.9)		(15.2)
Net loss attributable to non-controlling interest	—		—
Net loss attributable to Myriad Genetics Inc. stockholders	$	(37.9)	$	(15.2)
Loss per share:
Basic	$	(0.50)	$	(0.20)
Diluted	$	(0.50)	$	(0.20)
Weighted average shares outstanding:
Basic	75.3		74.7
Diluted	75.3		74.7


(in millions)	Quarters Ended
Consolidated Statement of Operations Data:	June 30, 2020		March 31, 2020		December 31, 2019 (a)		September 30, 2019
Molecular diagnostic testing	$	83.3	$	150.5	$	181.1	$	172.0
Pharmaceutical and clinical services	9.9		13.5		14.0		14.3
Total revenue	93.2		164.0		195.1		186.3
Costs and expenses:
Cost of molecular diagnostic testing	32.2		43.1		41.0		41.2
Cost of pharmaceutical and clinical services	4.5		7.0		8.6		8.5
Research and development expense	17.4		19.7		18.8		21.3
Change in the fair value of contingent consideration	—		(3.4)		(0.1)		0.7
Selling, general and administrative expense	107.4		132.9		134.3		135.5
Goodwill and intangible asset impairment charges	—		98.4		1.3		—
Total costs and expenses	161.5		297.7		203.9		207.2
Operating loss	(68.3)		(133.7)		(8.8)		(20.9)
Other income (expense):
Interest income	0.5		0.8		0.8		0.9
Interest expense	(3.1)		(2.3)		(2.5)		(2.9)
Other	12.4		4.1		(0.9)		0.6
Total other income (expense)	9.8		2.6		(2.6)		(1.4)
Loss before income taxes	(58.5)		(131.1)		(11.4)		(22.3)
Income tax benefit	(3.0)		(15.9)		(3.1)		(1.7)
Net loss	(55.5)		(115.2)		(8.3)		(20.6)
Net loss attributable to non-controlling interest	(0.1)		—		—		—
Net loss attributable to Myriad Genetics Inc. stockholders	$	(55.4)	$	(115.2)	$	(8.3)	$	(20.6)
Loss per share:
Basic	$	(0.74)	$	(1.55)	$	(0.11)	$	(0.28)
Diluted	$	(0.74)	$	(1.55)	$	(0.11)	$	(0.28)
Weighted average shares outstanding:
Basic	74.6		74.5		74.4		73.7
Diluted	74.6		74.5		74.4		73.7

(a) An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.


(in millions)	Quarters Ended
Consolidated Statement of Operations Data:	June 30, 2019		March 31, 2019		December 31, 2018		September 30, 2018
Molecular diagnostic testing	$	196.9	$	200.5	$	203.0	$	189.0
Pharmaceutical and clinical services	18.5		16.1		13.8		13.3
Total revenue	215.4		216.6		216.8		202.3
Costs and expenses:
Cost of molecular diagnostic testing	41.6		40.3		44.0		42.3
Cost of pharmaceutical and clinical services	9.0		8.3		8.1		7.4
Research and development expense	20.9		21.5		22.4		21.1
Change in contingent consideration	(0.3)		—		1.0		0.4
Selling, general and administrative expense	149.8		140.6		135.2		129.9
Total costs and expenses	221.0		210.7		210.7		201.1
Operating income (loss)	(5.6)		5.9		6.1		1.2
Other income (expense):
Interest income	0.9		0.7		0.9		0.7
Interest expense	(3.2)		(3.2)		(3.4)		(2.2)
Other	0.2		(0.1)		—		1.1
Total other expense	(2.1)		(2.6)		(2.5)		(0.4)
Income (loss) before income taxes	(7.7)		3.3		3.6		0.8
Income tax provision (benefit)	(3.4)		(3.6)		1.0		1.6
Net income (loss)	(4.3)		6.9		2.6		(0.8)
Net loss attributable to non-controlling interest	(0.1)		—		—		(0.1)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$	(4.2)	$	6.9	$	2.6	$	(0.7)
Earnings (loss) per share:
Basic	$	(0.06)	$	0.09	$	0.04	$	(0.01)
Diluted	$	(0.06)	$	0.09	$	0.03	$	(0.01)
Weighted average shares outstanding:
Basic	73.4		73.3		74.2		73.0
Diluted	74.8		74.9		76.5		73.0